The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: Prediction of equiefficient doses

Journal of Antimicrobial Chemotherapy

Volumn 48, Issue 6, 2001, Pages 821-826

  Zinner, Stephen H ^a   Firsov, Alexander A ^b   Gilbert, Deborah ^c   Simmons, Kelly ^c   Lubenko, Irene Yu ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI INFECTIVE AGENTS, FLUOROQUINOLONE; CIPROFLOXACIN; GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS, FLUOROQUINOLONE; AREA UNDER CURVE; CIPROFLOXACIN; COMPARATIVE STUDY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STREPTOCOCCUS PNEUMONIAE; SUPPORT, NON-U.S. GOV'T;

EID: 0035655140     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/48.6.821     Document Type: Article

References (26)

1. Bauernfeind, A., Eberlein, E. & Schneider, I. (1998). Comparative bactericidal kinetics of gatifloxacin (AM 1155) at various dosages in a pharmacodynamic model. Antiinfective Drugs and Chemotherapy 16, Suppl. 1, 69.
2. Lister, P. D. & Black, J. A. (2000). Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of AUC:MIC ratios on eradication. In Program and Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000. Abstract A294, p. 8. American Society for Microbiology, Washington, DC.
3. Vostrov, S. N., Kononenko, O. V., Lubenko, I. Y., Zinner, S. H. & Firsov, A. A. (2000). Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrobial Agents and Chemotherapy 44, 879-84.
4. Zinner, S., Gilbert, D. & Simmons, K. (1998). Activity of simulated oral dosing of gatifloxacin against Streptococcus pneumoniae in an in vitro dynamic model. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E188, p. 223. American Society for Microbiology, Washington, DC.
5. Blaser, J., Stone, B. B. & Zinner, S. H. (1985). Two-compartment kinetic model with multiple artificial capillary units. Journal of Antimicrobial Chemotherapy 15, Suppl. A, 131-7.
6. Kusajima, H., Koseki, N. & Ohkubo, H. Pharmacokinetics of BMS-206584; 200 mg oral dose with concurrent probenecid in humans. Bristol-Myers Squibb Pharmaceutical Research Institute Report No. 910058296.
7. Kusajima, H., Koseki, N. & Ohkubo, H. Phase I trial of a single intravenous infusion of BMS-206584 (AM-1155) in healthy male volunteers. Bristol-Myers Squibb Pharmaceutical Research Institute Report No. 910058297.
8. Kusajima, H., Koseki, N. & Ohkubo, H. Oral dose phase I study of AM-1155 (BMS-206584). Bristol-Myers Squibb Pharmaceutical Research Institute Report No. 910058295.
9. Bergan, T. & Thorsteinsson, S. B. (1986). Pharmacokinetics and bioavailability of ciprofloxacin. In Proceedings of the First International Ciprofloxacin Workshop, Current Clinical Practice Series 34, (Neu, H. C. & Weuta, H., Eds), pp. 111-21. Excerpta Medica, Amsterdam.
10. Hoffken, G., Lode, H., Prinzing, C., Borner, K. & Koeppe, P. (1985). Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 27, 375-9.
11. Wise, R., Lister, D., McNulty, C. A. M., Griggs, D. & Andrews, J. M. (1986). The comparative pharmacokinetics of five quinolones. Journal of Antimicrobial Chemotherapy 18, Suppl. D, 71-81.
12. Firsov, A. A., Chernykh, V. M. & Navashin, S. M. (1991). Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 34, 1312-7.
13. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A. & Cornaglia, G. (1997). Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration - time curve relationships: action of ciprofloxacin against Escherichia coli in an in-vitro dynamic model. Antimicrobial Agents and Chemotherapy 41, 1281-7.
14. Navashin, S. M., Fomina, I. P., Chernykh, V. M., Nazarov, A. D. & Firsov, A. A. (1986). Microcalorimetric method in kinetic study of aminoglycoside antimicrobial action on Gram-negative bacteria. In Abstracts of the Ninth International Congress of Infectious and Parasitic Diseases, Munich, 1986. Abstract 1394. Futuramed Verlag, München.
15. White, C. A. & Toothaker, R. (1985). Influence of ampicillin elimination half-life on in-vitro bactericidal effect. Journal of Antimicrobial Chemotherapy 15, Suppl. A, 257-60.
16. Bauernfeind, A. (1997). Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 639-51.
17. Jones, R. N., Pfaller, M. A., Doern, G. V. & Beach, M. (1998). Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23000 recent clinical isolates from the SENTRY antimicrobial surveillance program. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E194, p. 225. American Society for Microbiology, Washington, DC.
18. Hoellman, D. B., Jacobs, M. R. & Appelbaum, P. C. (1998). Antipneumococcal activity of gatifloxacin compared to eight other compounds by agar dilution MIC and time - kill testing. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E175, p. 220. American Society for Microbiology, Washington, DC.
19. Minassian, B., Warr, G., Kolek, B., Ryan, B., Fung-Tomc, J. & Bonner, D. (1998). In vitro activity of gatifloxacin against gram-positive aerobic bacteria, including Mycobacterium spp. In Program and Abstracts of the Thirty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract E181, p. 221. American Society for Microbiology, Washington, DC.
20. Schimitz, F.-J., Fluit, A. C., Verhoef, J., Köhrer, K. & Milatovic, D. (2000). In-vitro activity of three quinolones against 2341 gram-positive cocci and correlation of MIC-values with mutations in the quinolone resistance determining regions. Antiinfective Drugs and Chemotherapy 17, 31.
21. Firsov, A. A., Savarino, D., Ruble, M., Gilbert, D., Manzano, B., Medeiros, A. A. et al. (1996). Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrobial Agents and Chemotherapy 40, 734-8.
22. Firsov, A., Zinner, S., Vostrov, S., Gugutsidze, E. & Kononenko, O. (1999). The slopes of the AUC/MIC relationships of the anti-pneumococcal effect of grepafloxacin and ciprofloxacin in an in vitro dynamic model are related to inherent pharmacokinetic differences. In Program and Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 4.A-17, p. 5. American Society for Microbiology, Washington, DC.
23. Firsov, A. A., Lubenko, I. Y., Vostrov, S. N., Kononenko, O. V., Zinner, S. H. & Portnoy, Y. A. (2000). Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. Journal of Antimicrobial Chemotherapy 46, 725-32.
24. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A., Zinner, S. H. & Portnoy, Y. A. (1998). A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrobial Agents and Chemotherapy 42, 2841-7.
25. Firsov, A. A., Zinner, S. H., Lubenko, I. Y. & Vostrov, S. N. (2000). Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. International Journal of Antimicrobial Agents 16, 407-14.
26. Firsov, A. A., Vostrov, S. N., Lubenko, I. Yu., Kononenko, O. V., Zinner S. H. & Cornaglia, G. (1999). A comparison of the AUC/MIC-response plots of gemifloxacin and ciprofloxacin: critical value of the AUC/MIC ranges simulated in an in vitro dynamic model. Journal of Antimicrobial Chemotherapy 44, Suppl. A, 130.